Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$5.98 – $9.00
40% from low
Exchange
OTC Link
ADRC
Borrow rate
5.14%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $25.5M | $31.0M | $32.6M | $48.0M | $65.7M | $78.3M | $88.2M | $95.0M |
| Cost of revenue | $949.8K | $445.4K | $14.1M | $12.8M | $19.1M | $27.7M | $7.7M | $15.9M |
| Gross profit | $24.5M | $30.6M | $18.4M | $35.2M | $46.6M | $50.6M | $80.4M | $79.1M |
| Gross margin | 96.3% | 98.6% | 56.6% | 73.4% | 70.9% | 64.6% | 91.2% | 83.3% |
| R&D | $53.6K | $91.5K | $341.3K | $547.6K | $1.2M | $1.3M | $1.5M | $4.8M |
| Operating income | $12.2M | $16.7M | $10.2M | $26.7M | $33.1M | $40.9M | $48.0M | $45.7M |
| EBITDA | $12.3M | $16.8M | $10.6M | $28.2M | $33.8M | $41.7M | $56.3M | $57.2M |
| Net income | $13.2M | $18.1M | $16.6M | $24.7M | $20.9M | $30.6M | $35.6M | $36.2M |
| Net margin | 51.9% | 58.4% | 51.1% | 51.5% | 31.8% | 39.1% | 40.4% | 38.1% |
| EPS (diluted) | 0.27 | 0.37 | 0.30 | 0.48 | 0.40 | 0.59 | 0.70 | 0.72 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $102M | $0.73 | $0.70–$0.79 | 1 |
| 2027 | $108M | $0.77 | $0.74–$0.83 | 1 |
| 2028 | $126M | $1.12 | $1.06–$1.20 | 1 |
| 2029 | $438M | $4.60 | $4.37–$4.94 | 1 |
Forward consensus · source: Financial Modeling Prep
CLINUVEL PHARMS LTD S/ADR
No one on the platform currently holds CLVLY.
No tracked institution reports a position in CLVLY as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2025-09-08 | $0.0329 | 2025-09-29 |
| 2024-09-09 | $0.0340 | 2024-09-30 |
| 2023-09-07 | $0.0324 | 2023-10-02 |
No one on the platform has traded CLVLY yet.
| $342M |
| — |
| FGHQFFrontage Holdings Corporation | $0.14 | +0.00% | $274M | — |
| HLOSFHealios K.K. | $1.80 | +0.00% | $194M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 6.6× earnings vs its 21.5× historical median P/E.
Fair value ≈ $23.43 · price $7.20 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.